Each year IPHARMA takes part in DIA (Drug Information Association) Global Conferences in Europe and the USA. During the event, participants share their views and knowledge and establish international contacts with potential partners and clients, which leads to a development in pharmaceutical industry.
Within the frame of DIA 2016 52st Annual Meeting, which took place on June 26-30, 2016 in Pennsylvania Convention Center, Philadelphia, Natalia Vostokova (IPHARMA COO) presented a report on «Adaptive design in dose selection study of next-in-class NNRTI».
The study objective was to assess effects of different dosing regimens of Elpida® (Elpivirine) in combination with conventional antiretroviral therapy (ART) on treatment efficacy in treatment-naïve HIV-1 infected patients.
The use of adaptive design provides an opportunity to improve timeline and resources when selecting dosing regimens and evaluating drug efficacy. IPHARMA successfully uses current methods in clinical study design development.
Adaptive design in dose selection study of next-in-class NNRTI
«IPHARMA» LLC – an accredited partner of the «Skolkovo» Technopark, Contract Research Organization (CRO), specialized in conducting clinical trials of innovative drugs from Russian and foreign developers. IPHARMA is a clinical CRO of the ChemRar Group.
The main competence of the company is the effective and rational organization of clinical trials according to international standards as well as the drug registration support in Russia. IPHARMA team consists of the qualified specialists with an extensive experience in international and local clinical trials. The company has a large scientific background, its own medical expertise and an ability to involve top Russian and foreign specialists.